WEX is developing a new class of non-opioid analgesics. The Company’s proprietary platform is Tetrodotoxin (TTX), a highly selective sodium channel blocker. WEX’s lead product based on TTX is in Phase III clinical development for the treatment of cancer related pain and in Phase II for chemotherapy induced neuropathic pain.
WEX has conducted 15 clinical trials with TTX, with more than 718 patients treated to date.
WEX is a subsidiary of CK Life Sciences Int’l., (Holdings) Inc. (“CKLS”), listed on The Stock Exchange of Hong Kong Limited (stock code: 0775). CKLS is engaged in the business of research and development, manufacturing, commercialization, marketing and selling of environmental and human health products, and water businesses and investment in various financial and investment products. CKLS is a member of the CK Hutchison Group. For additional information, please visit www.ck-lifesciences.com.